Skip to main content

Table 1 Inclusion / exclusion criteria

From: A systematic review of lenvatinib and sorafenib for treating progressive, locally advanced or metastatic, differentiated thyroid cancer after treatment with radioactive iodine

Criteria Inclusion Exclusion
Patient population Adults with progressive, locally advanced or metastatic, differentiated thyroid carcinoma, refractory to radioactive iodine Patients with other types of thyroid cancer or diseases
Interventions Lenvatinib or sorafenib monotherapy (or in combination with best supportive care) Lenvatinib or sorafenib in combination with other agents
Comparatorsa Lenvatinib or sorafenib monotherapy (or in combination with best supportive care), best supportive care, placebo A comparator other than lenvatinib, sorafenib, best supportive care, placebo
Outcomes The outcome measures to be considered include: overall survival, progression-free survival, response rate, adverse effects of treatment, health-related quality of life No study was excluded based on outcomes
Study design Randomized controlled trials, systematic reviews,b prospective observational studies Retrospective cohort studies, case series, case reports, comments, letters, editorials, in vitro, animal, genetic or histochemical studies
  1. aWhere studies included a comparator arm
  2. bAt the inclusion stage, published reports of indirect comparisons were also included if the indirect comparison was based on RCT evidence, even if the conduct of a systematic review was not reported alongside the indirect comparison